News and Trends 11 Jul 2017 Novartis largely dodged deaths from its CAR-T therapy, but FDA still has safety concerns Editor’s Note: Novartis did note a death from cerebral hemorrhage in its hearing with the FDA yesterday. With the application review hearing set for tomorrow, the FDA has shared its thoughts on Novartis’ CAR-T candidate. Up front are serious safety concerns. Novartis’ CTL019, or Tisagenlecleucel, wowed the audience at ASH last fall with a stellar 82% […] July 11, 2017 - 3 minutesmins - By Evelyn Warner Share WhatsApp Twitter Linkedin Email
In Depth 11 Jul 2017 Regenerating the Body With Stem Cells – Hype or Hope? When the Japanese researcher Shinya Yamanaka managed to reprogram adult cells into an embryonic-like state to yield induced pluripotent stem cells (iPSCs), this was supposed to herald a revolution in regenerative medicine. But 10 years after their discovery, a therapeutic breakthrough is still outstanding. “The overall stem cell therapy field has failed today to show […] July 11, 2017 - 9 minutesmins - By Melanie De Almeida Share WhatsApp Twitter Linkedin Email
News and Trends 10 Jul 2017 You can buy DNA on Amazon, thanks to this Biotech Accelerator Steve O’Connell from RebelBio spoke to us about how far consumer biotech has come and synbio’s role in its democratization. Steve Jobs famously predicted that biology would one day go the way of computing and become available to the ordinary consumer. How is it progressing? “It’s already happening,” Steve O’Connell, Associate Director of RebelBio, told Philip […] July 10, 2017 - 2 minutesmins - By Evelyn Warner Share WhatsApp Twitter Linkedin Email
News and Trends 10 Jul 2017 Swiss Biotech Starts Phase II Trial to Treat Motor Symptoms of Parkinson’s Prexton Therapeutics has launched a Phase II trial to test whether its drug foliglurax can treat the motor complications of standard levodopa therapy. The Phase II trial will enroll 165 patients across the UK, Germany, France, Austria, Spain and Italy to monitor the effects of Prexton’s foliglurax. The company is looking for patients that have been treated […] July 10, 2017 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 10 Jul 2017 Danish Diabetes Biotech Shoots for a €75M IPO in the US Nasdaq Zealand Pharma, known for its partnership with Sanofi to boost the insulin blockbuster Lantus, is aiming high in an IPO on the US Nasdaq. Zealand Pharma has announced it has already filed for an IPO at the Nasdaq Global Select Market, an exclusive listing for large cap companies. Currently listed on the Nasdaq Copenhagen, Zealand Pharma […] July 10, 2017 - 1 minutemin - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 10 Jul 2017 Sanofi and US Partner Launch Phase III Trial in Hemophilia with RNAi Alnylam and its partner Sanofi are starting a Phase III program to enter its RNAi drug fitusiran in the competitive hemophilia market. Sanofi and its partner Alnylam have announced the start of a Phase III program that seeks to recruit 250 patients to test its RNAi drug fitusiran in patients with both hemophilia A and […] July 10, 2017 - 3 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 10 Jul 2017 This tech not only flags but also identifies and quantifies HCP contaminants If host cell proteins linger in your biological therapeutic, they can cause your clinical failure or regulatory rejection. Here’s how you can keep track of them. Today, biological drugs are generally produced in cell lines — from yeast, Chinese Hamsters, or a variety of other sources. It’s pretty cool that humans can manipulate these organisms […] July 10, 2017 - 4 minutesmins - By External Contributor Share WhatsApp Twitter Linkedin Email
Interview 10 Jul 2017 Meet the CEO of Minoryx, the Spanish Biotech Fighting Rare Disease I spoke with Marc Martinell, CEO of Minoryx, to learn first-hand how his company in Barcelona is bringing new hope for patients suffering from rare diseases. Having previously worked in Crystax Pharmaceuticals and Oryzon Genomics, Marc Martinell is now CEO of one of Spain’s most successful biotechs. Minoryx Therapeutics is developing what could be the first […] July 10, 2017 - 6 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 8 Jul 2017 Memories Encoded in DNA and Biological Reliques Margherita Pevere is an artist that uses living organisms to explore our relationship with nature and technology, and our obsession with preserving information. Margherita Pevere is an artist fascinated by the connection between humans and nature, and how the pervasive introduction of technology into all aspects of our lives is affecting this relationship. Her work puts living […] July 8, 2017 - 3 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 7 Jul 2017 French Mobile Diabetes Firm gets €17.5M to Build an Artificial Pancreas Cellnovo has launched a capital increase from top European investors to boost its mobile system for diabetes and complete the development of a fully automated artificial pancreas. Cellnovo is a French medtech company with an all-in-one system to manage diabetes in the market. The company has now announced a capital raise of €17.5M to boost […] July 7, 2017 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
Interview 7 Jul 2017 Video: The Naked Truth – How to Choose the Best Clinical Development Vendor! Two experts share their views on how to choose the best clinical development vendor. The selection process involves many different and varied factors! “Nowadays, vendor selection is part of a science, the science of making difficult choices,” Marc Riteco, Vice President of Clinical Development at uniQure, told the audience during our second Refresh Expert Track […] July 7, 2017 - 2 minutesmins - By External Contributor Share WhatsApp Twitter Linkedin Email
News and Trends 7 Jul 2017 Better than CRISPR? New Genetic Analysis Method ropes in Long-Read DNA Cloning After CRISPR, there’s a new genetic technique with a tongue-in-cheek name in town: LASSO cloning. Researchers from four institutions, including the US-based John Hopkins, Rutgers and Harvard, and the University of Trento in Italy, have developed a new technology to study large chunks of DNA and their function. The work behind it was recently published in Nature Biomedical […] July 7, 2017 - 3 minutesmins - By Denise Neves Gameiro Share WhatsApp Twitter Linkedin Email